{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:45:32Z","timestamp":1778910332232,"version":"3.51.4"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1686","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Valoctocogene roxaparvovec-rvox (Roctavian \u2013 Biomarin), an adeno-associated virus (AAV) vector-based gene therapy, has been approved by the FDA for one-time treatment of severe hemophilia A in adults without pre-existing antibodies to AAV serotype 5. It is the first gene therapy to be approved in the US for treatment of hemophilia A.<\/jats:p>","DOI":"10.58347\/tml.2023.1686c","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:21:09Z","timestamp":1695745269000},"page":"157-158","source":"Crossref","is-referenced-by-count":1,"title":["Valoctocogene Roxaparvovec (Roctavian) \u2013 A Gene Therapy for Severe Hemophilia A"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2023,10,2]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:21:09Z","timestamp":1695745269000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1686c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":0,"journal-issue":{"issue":"1686","published-online":{"date-parts":[[2023,10,2]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1686c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]}}}